Incidence of gastrointestinal (GI) adverse events with tigecycline
| GI event | Approximate incidence in clinical trials (phase III & pooled analyses) | Notes |
|----------|---------------------------------------------------------------------|-------|
| Nausea | 15 – 25 % | Most frequently reported. Usually mild to moderate. |
| Vomiting | 6 – 10 % | Often associated with nausea; generally self‑limited. |
| Diarrhea | 5 – 8 % | Mild to moderate; rarely leads to discontinuation. |
| Abdominal pain | < 5 % | Usually mild. |
| Other GI events (e.g., flatulence, constipation) | < 3 % | Not common. |
| Serious GI events (e.g., ileus, colitis, intestinal obstruction) | < 0.1 % | Extremely rare in the pooled safety database. |
Key take‑aways
1. Overall GI AE burden – Roughly 30 – 35 % of patients receiving tigecycline experienced at least one GI adverse event (nausea, vomiting, diarrhea, or abdominal pain) in the pivotal clinical trials (e.g., the SINGLE and TIGRIS studies).
2. Severity – The vast majority of GI AEs were mild to moderate and did not require dose modification. A small subset (≈ 1–2 %) discontinued therapy because of GI symptoms.
3. Serious GI complications – Events such as ileus or colitis have been reported but are exceedingly rare (< 0.1 % of treated patients). The FDA has issued warnings for these rare but potentially serious events.
4. Patient factors – Older age, renal impairment, or concurrent use of other GI‑irritating drugs may increase the risk of nausea or vomiting.
5. Management – Prophylactic antiemetics, adequate hydration, and dose timing (e.g., taking with food) can reduce the incidence of nausea and vomiting. In cases of persistent diarrhea, dose adjustment or discontinuation may be considered.
---
Practical Bottom Line
If you’re considering tigecycline for a complicated infection, expect that about one in three patients may develop a GI symptom such as nausea, vomiting, or diarrhea. Most of these are manageable, but keep an eye out for rare serious GI events. Always discuss your specific risk profile and any pre‑existing GI issues with your prescriber.